Genetic News

A combination therapy of gemcitabine, capecitabine and bevacizumab improves outcomes in patients with advanced pancreatic cancer, according to a multi-center study led by researchers at Roswell Park Cancer Institute in Buffalo, N.Y. Read the rest of this entry »

Colon cancer patients who have the normal version of a particular gene are more likely to benefit from a combination treatment that includes adding the targeted therapy Erbitux to chemotherapy. Read the rest of this entry »